Pages

▼
Wednesday, November 16, 2022

Results from MultiPepT1De (Multi Peptide Vaccine) by Powrie at King’s College London

›
This is the most recent result from a long line of research led by Colin Dayan and Mark Peakman, at Cardiff University and King's Colleg...
Sunday, October 16, 2022

JDRF Funding for a Cure 2022

›
In the US, we are in the "Walking Season" when JDRF (Juvenile Diabetes Research Foundation) asks us to walk to raise money for a ...
Friday, September 16, 2022

Research Dropped As A Practical Cure

›
Every year I have the sad job of removing some projects from my list of active research aimed at curing T1D.  In the perfect world, I would...
Monday, July 11, 2022

Provention Bio Update

›
Provention Bio is a small biotech company targeting several autoimmune diseases.  It has two drug candidates which target T1D: teplizumab (P...
Wednesday, May 4, 2022

NN1845 (a glucose sensitive insulin) Starts A Second Phase-1 Clinical Trail

›
One approach to creating a "practical cure" for T1D is sometimes called "smart insulin", "glucose sensitive insulin...
Tuesday, April 5, 2022

ViaCyte and CRISPR start a Phase-I Clinical Trial (VCTX210A-101)

›
For many years, it has been clear that one possible path to a cure is to transplant new beta cells and also in some way prevent the body fro...
Monday, March 21, 2022

Update On Teplizumab from Provention Bio

›
Teplizumab is a proposed treatment which, if given to someone at-risk for type-1 diabetes (T1D), can delay or possibly prevent the onset of ...